Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) disclosed that it has received the FDA authorization for LUPKYNIS™ (voclosporin). To treat Lupus Nephritis, LUPKYNIS is the first oral therapy that has got the endorsement of the FDA to treat adult sufferers with active lupus nephritis.
